Ligand Pharmaceuticals (LGND) Q4 2024 earnings summary

Executive summary

• Achieved strong financial and operational performance in 2024, with total revenue up 27% to $167.1 million and royalty revenue up 28%, driven by new product approvals and portfolio expansion.

• Transformed into a profitable, infrastructure-light, and economically diversified organization, focusing on high-value royalty assets and scalable growth.

• Portfolio expanded to 12 major commercial-stage royalty assets, with key launches and approvals in 2024 including Ohtuvayre, Capvaxive, ZELSUVMI, and full FDA approval for FILSPARI.

• Added Qarziba to the portfolio and closed a $75 million royalty financing with Castle Creek Biosciences for D-Fi, marking the first move into cell and gene therapy.

• Generated over $100 million in cash from operations, ending 2024 with $256 million in cash and investments and no debt.

Financial highlights

• Total 2024 revenue grew 27% year-over-year to $167.1 million; royalty revenue up 28% to $108.8 million.

• Q4 2024 revenue increased 52% to $42.8 million, with royalties up 55% to $34.8 million compared to Q4 2023.

• Core adjusted EPS rose over 40% to $5.74 per share; adjusted net income (excluding Viking stock gains) was $108.5 million.

• Ended 2024 with $256 million in cash and investments, no debt, and access to a $125 million credit facility (expandable to $175 million).

• Operating cash flow exceeded $100 million in 2024.

Outlook and guidance

• 2025 royalty revenue guidance: $135–$140 million; total revenue: $180–$200 million; adjusted EPS: $6.00–$6.25.

• Long-term royalty receipts projected to grow at a 22%+ CAGR from 2024–2029, supported by commercial and late-stage pipeline assets.

• Royalty revenue growth expected to be driven by FILSPARI, Ohtuvayre, Capvaxive, and new investments.

• Anticipates ZELSUVMI launch by mid-2025 and multiple value-creating milestones.